Playlist


The President of Turkmenistan has signed a formal decree outlining the arrangements for the upcoming session of the CIS Council of Heads of Government in the nation’s capital. The summit, scheduled for May 22, 2026, is a cornerstone of Turkmenistan's chairmanship of the Commonwealth of Independent States for the current year. The presidential directive mandates that the event be organized to the highest international standards of excellence.
The preparation process involves a coordinated effort between the Presidential Administration’s Department of Management, the Ministry of Foreign Affairs, and the CIS Executive Committee. This multilateral collaboration is aimed at ensuring a seamless organizational framework for the high-level delegates. The summit serves as a practical implementation of the concept approved for Turkmenistan’s 2026 CIS presidency, focusing on regional integration and strategic dialogue.
Key topics on the summit’s agenda are expected to include economic cooperation, logistical connectivity, and humanitarian exchange within the Commonwealth. Ashgabat continues to demonstrate its role as a pivotal diplomatic hub, facilitating discussions that promote stability and sustainable growth across the region. The meeting will provide a vital platform for heads of government to review joint initiatives and endorse new multilateral agreements.
As the host nation, Turkmenistan is dedicated to creating a constructive environment for high-level decision-making and international diplomacy. Extensive measures are being taken to ensure the successful delivery of the forum, highlighting the country's logistical capabilities and commitment to regional partnership. The documents resulting from the May session are anticipated to shape the future trajectory of governmental cooperation among member states.
Also read


Simple Vitamin Shows Surprising Results in Pre-Cancerous Blood Conditions, Study Finds
Today in 02:02Daily high-dose supplementation of vitamin C can significantly reduce mortality risks and help prevent severe medical complications in patients with pre-cancerous blood conditions. Researchers from the Van Andel Institute in the United States and Copenhagen University Hospital in Denmark reached this conclusion following a comprehensive three-year follow-up study. The international "EVITA" trial involved volunteers who were administered 1,000 mg of vitamin C daily over the course of a year, while a control group received a placebo.
Although initial hypotheses suggested vitamin C might directly inhibit abnormal cell proliferation, researchers found its primary benefit lay in strengthening the body, reducing systemic inflammation, and lowering rates of anemia, pneumonia, and internal bleeding. Over the three-year observation period, the vitamin C group exhibited a significantly higher survival rate compared to the placebo group. While experts emphasize that these findings remain preliminary and require larger clinical trials before reshaping formal medical treatment protocols, vitamin C continues to show promising potential in supportive patient care.